Fig. 4: Mal LbL NP drives strong antitumour activity and boosts T cell tumour infiltration.
From: IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer
a–d, B6C3F1 mice (one cohort of n = 10 animals per group) inoculated with 106 HM-1-luc tumour cells on day 0 were treated on days 7 and 14 with 20 µg of IL-12 as a free cytokine or conjugated to NPs. Experimental timeline (a), IVIS whole-animal i.p. BLI readings (mean ± s.d.; b) and overall survival (c). On day 30, PBMCs of surviving and naive mice (n = 5 animals) were analysed via IFN-γ ELISpot restimulated with HM-1-luc tumour cells. Quantitation of spots detected (mean ± s.d.; d) are shown. e–k, B6C3F1 mice inoculated with 106 HM-1 tumour cells on day 0 were treated on day 10 with 20 µg of IL-12 as a free cytokine or conjugated to Mal NPs (UL and LbL). Two days after dosing, ascites (n = 6 per group) and i.p. tumour nodules (primarily omentum tissue, n = 4 per group) were harvested and processed for flow cytometry analysis. Timeline for experiment (e), representative flow plots of T cell (CD45+CD3+) in ascites fluid (f), quantitation of T cells in ascites fluid (g), quantitation of CD8+ to CD4+ T cell ratio in ascites fluid (h), representative flow plots of T cell (CD45+CD3+) in tumour nodules (i), quantitation of T cells in tumour nodules (j) and quantitation of CD8+ to CD4+ T cell ratio in tumour nodules (k). Statistics derived using all n from experiment with each animal as a data point. P values were determined by the log-rank (Mantel–Cox) test (c) and one-way ANOVA followed by Tukey’s multiple comparison test (d, g, h, j and k).
